NCT00932646 - Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2010

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BI 1744 (Olodaterol) Low Dose

BI1744 Respimat low dose once daily and placebo Foradil

DRUG

BI 1744 (Olodaterol) Medium Dose

BI1744 Respimat medium dose once daily and placebo Foradil

DRUG

Placebo

Placebo Respimat once daily and placebo Foradil

DRUG

Foradil

12 mcg twice daily and placebo Respimat

Trial Locations (13)

1222.25.25009 Boehringer Ingelheim Investigational Site, Jasper

1222.25.25002 Boehringer Ingelheim Investigational Site, Clearwater

1222.25.25003 Boehringer Ingelheim Investigational Site, DeLand

1222.25.25007 Boehringer Ingelheim Investigational Site, Winter Park

1222.25.25010 Boehringer Ingelheim Investigational Site, Austell

1222.25.25008 Boehringer Ingelheim Investigational Site, Albuquerque

1222.25.25012 Boehringer Ingelheim Investigational Site, Charlotte

1222.25.25004 Boehringer Ingelheim Investigational Site, Raleigh

1222.25.25011 Boehringer Ingelheim Investigational Site, Columbus

1222.25.25014 Boehringer Ingelheim Investigational Site, Seneca

1222.25.25006 Boehringer Ingelheim Investigational Site, Knoxville

1222.25.25005 Boehringer Ingelheim Investigational Site, Houston

1222.25.25013 Boehringer Ingelheim Investigational Site, Richmond